Obesity pipeline
What is next, and who is running it?
The next dated milestone on each program. A hollow marker is a registry primary completion date, not a company readout.
ClassNone selected
MechanismNone selected
83 of 94 programs on this timeline
202520262027202820292030Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Today
Abbott 1
SibutraminePhase 3
No dated milestone in 2025 to 2030
AbbVie 1
ABBV-295Phase 2
No dated milestone in 2025 to 2030
Aconcagua Bio, Inc 1
ACCG-2671Phase 1/2
No dated milestone in 2025 to 2030
Altimmune 1
PemvidutidePhase 2
No dated milestone in 2025 to 2030
Amgen 1
Maridebart CafraglutidePhase 3
No dated milestone in 2025 to 2030
Arrowhead 1
ARO-ALK7Phase 1/2
No dated milestone in 2025 to 2030
Ascletis Pharma (China) Co 1
ASC30Phase 3
No dated milestone in 2025 to 2030
AstraZeneca 4
ElecoglipronPhase 3
No dated milestone in 2025 to 2030
ExenatidePhase 3
No dated milestone in 2025 to 2030
PramlintidePhase 2/3
No dated milestone in 2025 to 2030
AZD6234Phase 3
No dated milestone in 2025 to 2030
Biohaven Therapeutics 1
TaldefgrobepPhase 2
No dated milestone in 2025 to 2030
Boehringer Ingelheim 1
SurvodutidePhase 3
No dated milestone in 2025 to 2030
BrightGene Bio-Medical Technology Co 1
BGM0504Phase 3
No dated milestone in 2025 to 2030
Carmot Therapeutics, Inc 1
CT-868Phase 2
No dated milestone in 2025 to 2030
Company n/r 3
BeinaglutideStage n/r
No dated milestone in 2025 to 2030
DulaglutidePhase 3
No dated milestone in 2025 to 2030
LoxenatidePhase 2/3
No dated milestone in 2025 to 2030
CSPC Baike (Shandong) Biopharmaceutical Co 1
TG103Phase 3
No dated milestone in 2025 to 2030
Eli Lilly 7
TirzepatideApproved
No dated milestone in 2025 to 2030
OrforglipronApproved
No dated milestone in 2025 to 2030
RetatrutidePhase 3
No dated milestone in 2025 to 2030
EloralintidePhase 3
No dated milestone in 2025 to 2030
Eloralintide And TirzepatidePhase 3
No dated milestone in 2025 to 2030
LY4086940Phase 2
No dated milestone in 2025 to 2030
BimagrumabPhase 2
No dated milestone in 2025 to 2030
Empros Pharma AB 1
OrlistatApproved
No dated milestone in 2025 to 2030
Fujian Shengdi Pharmaceutical Co 1
RibupatidePhase 3
No dated milestone in 2025 to 2030
Gan & Lee Pharmaceuticals 1
BofanglutidePhase 3
No dated milestone in 2025 to 2030
Gasherbrum Bio, Inc 1
AleniglipronPhase 3
No dated milestone in 2025 to 2030
GSK 1
AlbiglutidePhase 3
No dated milestone in 2025 to 2030
Guangdong Raynovent Biotech Co 1
RAY1225Phase 3
No dated milestone in 2025 to 2030
Hangzhou Sciwind Biosciences Co 1
EcnoglutidePhase 3
No dated milestone in 2025 to 2030
Hengrui 1
NoiiglutidePhase 3
No dated milestone in 2025 to 2030
Huadong Medicine 3
HDM1002Phase 3
No dated milestone in 2025 to 2030
HDM1702Phase 3
No dated milestone in 2025 to 2030
HDM1005Phase 3
No dated milestone in 2025 to 2030
Innovent 1
MazdutidePhase 3
No dated milestone in 2025 to 2030
Inversago Pharma 1
MonlunabantPhase 2
No dated milestone in 2025 to 2030
MindRank AI Ltd 1
MDR-001Phase 3
No dated milestone in 2025 to 2030
NeuroSearch 1
TesofensinePhase 2
No dated milestone in 2025 to 2030
Novo Nordisk 9
SemaglutideApproved
No dated milestone in 2025 to 2030
No dated milestone in 2025 to 2030
ZenagamtidePhase 3
No dated milestone in 2025 to 2030
LiraglutideApproved
No dated milestone in 2025 to 2030
Oral SemaglutidePhase 3
No dated milestone in 2025 to 2030
CagrilintidePhase 3
No dated milestone in 2025 to 2030
NNC0519-0130Phase 2
No dated milestone in 2025 to 2030
NNC0165-1875Phase 2
No dated milestone in 2025 to 2030
LorcaserinPhase 1/2
No dated milestone in 2025 to 2030
Orexigen Therapeutics, Inc 1
Naltrexone And BupropionPhase 3
No dated milestone in 2025 to 2030
PegBio Co 1
VisepegenatidePhase 1/2
No dated milestone in 2025 to 2030
Pfizer 4
BerobenatidePhase 3
No dated milestone in 2025 to 2030
MET-233IPhase 1/2
No dated milestone in 2025 to 2030
PF-07976016Phase 2
No dated milestone in 2025 to 2030
LotiglipronPhase 2
No dated milestone in 2025 to 2030
Regeneron 3
HS-20094Phase 3
No dated milestone in 2025 to 2030
GaretosmabPhase 2
No dated milestone in 2025 to 2030
TrevogrumabPhase 2
No dated milestone in 2025 to 2030
Rhythm 2
SetmelanotidePhase 3
No dated milestone in 2025 to 2030
LB54640Phase 2
No dated milestone in 2025 to 2030
Roche 3
PetrelintidePhase 3
No dated milestone in 2025 to 2030
TaspoglutidePhase 3
No dated milestone in 2025 to 2030
CT-388Phase 3
No dated milestone in 2025 to 2030
Sanofi 3
LixisenatidePhase 3
No dated milestone in 2025 to 2030
RimonabantPhase 3
No dated milestone in 2025 to 2030
EfpeglenatidePhase 3
No dated milestone in 2025 to 2030
Scholar Rock 1
ApitegromabPhase 2
No dated milestone in 2025 to 2030
Shandong Suncadia Medicine Co 1
SafiglipronPhase 3
No dated milestone in 2025 to 2030
Shanghai Yinnuo Pharmaceutical Technology Co 1
Efsubaglutide AlfaPhase 2/3
No dated milestone in 2025 to 2030
Shanghai Yinnuo Pharmaceutical Technology Co. 1
SupaglutidePhase 2/3
No dated milestone in 2025 to 2030
Shionogi 1
VelneperitPhase 2
No dated milestone in 2025 to 2030
Skye Bioscience 1
NimacimabPhase 2
No dated milestone in 2025 to 2030
Terns, Inc 1
TERN-601Phase 2
No dated milestone in 2025 to 2030
The United Bio-Technology (Hengqin) Co 1
UBT251Phase 3
No dated milestone in 2025 to 2030
Verdiva Bio Dev Limited 1
VRB-101Phase 2
No dated milestone in 2025 to 2030
Veru Inc 1
EnobosarmPhase 2
No dated milestone in 2025 to 2030
Viking Therapeutics 2
VK2735Phase 3
No dated milestone in 2025 to 2030
Oral VK2735Phase 3
No dated milestone in 2025 to 2030
Vincentage Pharma Co 1
VCT220Phase 3
No dated milestone in 2025 to 2030
VIVUS 1
Phentermine And TopiramatePhase 3
No dated milestone in 2025 to 2030
Zafgen 1
BeloranibPhase 3
No dated milestone in 2025 to 2030
Zealand Pharma 1
DapiglutidePhase 2
No dated milestone in 2025 to 2030